IBDEI26T ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,36728,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,36728,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,36729,0)
 ;;=D56.3^^169^1858^18
 ;;^UTILITY(U,$J,358.3,36729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36729,1,3,0)
 ;;=3^Thalassemia minor
 ;;^UTILITY(U,$J,358.3,36729,1,4,0)
 ;;=4^D56.3
 ;;^UTILITY(U,$J,358.3,36729,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,36730,0)
 ;;=D56.5^^169^1858^7
 ;;^UTILITY(U,$J,358.3,36730,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36730,1,3,0)
 ;;=3^Hemoglobin E-beta thalassemia
 ;;^UTILITY(U,$J,358.3,36730,1,4,0)
 ;;=4^D56.5
 ;;^UTILITY(U,$J,358.3,36730,2)
 ;;=^340498
 ;;^UTILITY(U,$J,358.3,36731,0)
 ;;=D56.8^^169^1858^19
 ;;^UTILITY(U,$J,358.3,36731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36731,1,3,0)
 ;;=3^Thalassemias NEC
 ;;^UTILITY(U,$J,358.3,36731,1,4,0)
 ;;=4^D56.8
 ;;^UTILITY(U,$J,358.3,36731,2)
 ;;=^5002305
 ;;^UTILITY(U,$J,358.3,36732,0)
 ;;=D57.3^^169^1858^16
 ;;^UTILITY(U,$J,358.3,36732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36732,1,3,0)
 ;;=3^Sickle-cell trait
 ;;^UTILITY(U,$J,358.3,36732,1,4,0)
 ;;=4^D57.3
 ;;^UTILITY(U,$J,358.3,36732,2)
 ;;=^5002313
 ;;^UTILITY(U,$J,358.3,36733,0)
 ;;=D57.1^^169^1858^13
 ;;^UTILITY(U,$J,358.3,36733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36733,1,3,0)
 ;;=3^Sickle-cell disease without crisis
 ;;^UTILITY(U,$J,358.3,36733,1,4,0)
 ;;=4^D57.1
 ;;^UTILITY(U,$J,358.3,36733,2)
 ;;=^5002309
 ;;^UTILITY(U,$J,358.3,36734,0)
 ;;=D57.02^^169^1858^6
 ;;^UTILITY(U,$J,358.3,36734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36734,1,3,0)
 ;;=3^Hb-SS disease with splenic sequestration
 ;;^UTILITY(U,$J,358.3,36734,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,36734,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,36735,0)
 ;;=D57.01^^169^1858^4
 ;;^UTILITY(U,$J,358.3,36735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36735,1,3,0)
 ;;=3^Hb-SS disease with acute chest syndrome
 ;;^UTILITY(U,$J,358.3,36735,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,36735,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,36736,0)
 ;;=D57.00^^169^1858^5
 ;;^UTILITY(U,$J,358.3,36736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36736,1,3,0)
 ;;=3^Hb-SS disease with crisis, unspecified
 ;;^UTILITY(U,$J,358.3,36736,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,36736,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,36737,0)
 ;;=D57.20^^169^1858^17
 ;;^UTILITY(U,$J,358.3,36737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36737,1,3,0)
 ;;=3^Sickle-cell/Hb-C disease without crisis
 ;;^UTILITY(U,$J,358.3,36737,1,4,0)
 ;;=4^D57.20
 ;;^UTILITY(U,$J,358.3,36737,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,36738,0)
 ;;=D57.811^^169^1858^10
 ;;^UTILITY(U,$J,358.3,36738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36738,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Acute Chest Syndrome NEC
 ;;^UTILITY(U,$J,358.3,36738,1,4,0)
 ;;=4^D57.811
 ;;^UTILITY(U,$J,358.3,36738,2)
 ;;=^5002318
 ;;^UTILITY(U,$J,358.3,36739,0)
 ;;=D57.812^^169^1858^11
 ;;^UTILITY(U,$J,358.3,36739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36739,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,36739,1,4,0)
 ;;=4^D57.812
 ;;^UTILITY(U,$J,358.3,36739,2)
 ;;=^5002319
 ;;^UTILITY(U,$J,358.3,36740,0)
 ;;=D57.819^^169^1858^12
 ;;^UTILITY(U,$J,358.3,36740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36740,1,3,0)
 ;;=3^Sickle-Cell Disorders w/ Unspec Crisis NEC
 ;;^UTILITY(U,$J,358.3,36740,1,4,0)
 ;;=4^D57.819
 ;;^UTILITY(U,$J,358.3,36740,2)
 ;;=^5002320
 ;;^UTILITY(U,$J,358.3,36741,0)
 ;;=D58.8^^169^1858^9
 ;;^UTILITY(U,$J,358.3,36741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,36741,1,3,0)
 ;;=3^Hereditary Hemolytic Anemias NEC
